ITM Isotope Technologies Munich SE

ITM Isotope Technologies Munich SE is a privately held radiopharmaceutical biotechnology company founded in 2004. Headquartered in Garching, Germany, the company operates as a European company (Societas Europaea, "SE"). It is a venture-backed firm with investors that include Temasek, BlackRock, and the Qatar Investment Authority. Sources from 2024-2026 indicate the company has around 600 employees.

ITM is an operating company that develops, produces, and supplies medical radioisotopes and radiopharmaceuticals for the diagnosis and treatment of cancer. A key product is its no-carrier-added Lutetium-177 (n.c.a. 177Lu), sold under the brand name EndolucinBeta®, which is used in Targeted Radionuclide Therapy to destroy tumor cells. The company also has a proprietary pipeline of precision oncology treatments in clinical development for various cancers, including neuroendocrine tumors, prostate cancer, and glioblastomas.

As a patent litigant, ITM appears as an operating company using the patent system strategically rather than as a non-practicing entity (NPE). The company's sole tracked case is as a plaintiff at the Patent Trial and Appeal Board (PTAB), where parties can challenge the validity of issued patents. It has no tracked history of being a defendant in patent suits.

The company's one tracked case is ITM Isotope Technologies Munich SE v. The Johns Hopkins University, a 2024 proceeding before the PTAB. This action involves challenging a patent held by a major research university active in the same technology field, which is consistent with a competitive dispute between two operating entities.